
## Mark R Trusheim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5419821/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery, 2007, 6, 287-293.	46.4	438
2	Quantifying factors for the success of stratified medicine. Nature Reviews Drug Discovery, 2011, 10, 817-833.	46.4	90
3	Alternative State-Level Financing for Hepatitis C Treatment—The "Netflix Model― JAMA - Journal of the American Medical Association, 2018, 320, 1977.	7.4	58
4	Translational Medicine Guide transforms drug development processes: the recent Merck experience. Drug Discovery Today, 2016, 21, 517-526.	6.4	50
5	Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System. Value in Health, 2019, 22, 621-626.	0.3	48
6	Surface-modified photochemistry. Preparation of silica-supported triiron dodecacarbonyl via irradiation of absorbed iron pentacarbonyl. Journal of the American Chemical Society, 1982, 104, 6590-6596.	13.7	38
7	A Useful and Sustainable Role for Nâ€ofâ€1 Trials in the Healthcare Ecosystem. Clinical Pharmacology and Therapeutics, 2022, 112, 224-232.	4.7	25
8	Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discovery Today, 2022, 27, 17-30.	6.4	22
9	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discovery Today, 2021, 26, 399-415.	6.4	20
10	Economic challenges and possible policy actions to advance stratified medicine. Personalized Medicine, 2012, 9, 413-427.	1.5	19
11	Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development. Therapeutic Innovation and Regulatory Science, 2013, 47, 474-483.	1.6	19
12	Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. Forum for Health Economics and Policy, 2010, 13, .	0.8	18
13	Investigating investment in biopharmaceutical R&D. Nature Reviews Drug Discovery, 2016, 15, 673-674.	46.4	16
14	Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation. Therapeutic Innovation and Regulatory Science, 2016, 50, 347-354.	1.6	15
15	The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics. Drug Discovery Today, 2015, 20, 1439-1450.	6.4	13
16	Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users. Health Affairs, 2021, 40, 989-999.	5.2	13
17	Understanding the Rewards of Successful Drug Development — Thinking Inside the Box. New England Journal of Medicine, 2020, 382, 473-480.	27.0	12
18	Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. Pharmacogenomics, 2013, 14, 325-334.	1.3	11

MARK R TRUSHEIM

#	Article	IF	CITATIONS
19	Characterization of annual disease progression of multiple sclerosis patients: A population-based study. Multiple Sclerosis Journal, 2018, 24, 786-794.	3.0	10
20	Defining and quantifying the use of personalized medicines. Nature Reviews Drug Discovery, 2013, 12, 896-897.	46.4	8
21	The Janus initiative: A multi-stakeholder process and tool set for facilitating and quantifying Adaptive Licensing discussions. Health Policy and Technology, 2014, 3, 241-247.	2.5	8
22	Precision reimbursement for precision medicine: using real world evidence to evolve from trialâ€andâ€project to trackâ€andâ€pay to learnâ€andâ€predict Clinical Pharmacology and Therapeutics, 2021,	, <b>4.</b> 7	5
23	Personalized medicine and health economics: is small the new big? A white paper. Israel Medical Association Journal, 2013, 15, 602-7.	0.1	2
24	Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies. Data in Brief, 2022, 41, 107891.	1.0	1
25	Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. SSRN Electronic Journal, 2010, , .	0.4	0